Tumor Model Compendium web interface provides an online, easily accessible database of the company’s tumor models, Aidan Synnott, executive director, discovery oncology, Charles River, told us.
“This allows researchers to find a model based on specific histology or molecular property and the ability to do combination searches across several properties makes finding the right tumor model for a study much more efficient,” he said.
“It puts the power of our data in the hands of scientists.”
The collection includes tumor models from a range of tumor subtypes for in vivo and in vitro oncology research. It includes patient-derived xenografts (PDXs), cell line-derived xenografts (CDX), and syngeneic models.
The Compendium also includes human leukocyte antigen (HLA) subtyping data, the availability of which helps researchers understand and control immune system variability, according to the company.
“We’re excited that, with this update, we’re able to provide more accessible data on our tumor models, making the Compendium a powerful tool in in vitro as well as in vivo oncology research,” said Synnott.
“We’re seeing a definite shift toward in vitro oncology for early toxicity and patient identification, because it provides researchers a rapid and cost-effective way to test the efficacy of a compound.”
Charles River recently acquired KWS BioTest to expand the company’s immunology contract research services and geographical footprint, and just last week announced its purchase of the non-clinical CRO MPI Research for $800m (€648m).
Last year, the company also established partnerships with OcellO and InSphero AG as part of its stated commitment to the in vitro oncology space.